Quite a different tumor marker was selected during Selectikine (NHS-IL-2Lt, EMD521873) development, which consists of an IL-2 low-toxicity mutant (D20T) fused at the N terminus to a humanized NHS antibody targeted against DNA and histone complexes released at the necrotic core of tumors [81]. This evidence concerns the gene IL2 and neoplasm.